ICI therapy aims to overcome tumor immune escape through targeting immune inhibitory molecules (e.g., PD-1, PD-L1, LAG3, and CTLA4) expressed on the surfaces of tumor and immune cells [33,34,35]. This evidence concerns the gene CTLA4 and neoplasm.